The global acute myeloid leukemia (AML) therapeutics market is set to experience substantial growth, according to a new report from Fact.MR. The market is projected to expand from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, registering a compound annual growth rate (CAGR) of 9.2% between 2026 and 2036. This growth represents an absolute dollar opportunity of approximately USD 5.9 billion, with the market nearly doubling in value over the forecast period. The expansion reflects a paradigm shift in AML treatment, moving from traditional chemotherapy toward genomics-driven strategies and targeted therapies that offer more personalized care.
Precision medicine is at the forefront of this transformation. Physicians are increasingly relying on molecular diagnostics and genomic profiling to guide treatment decisions. Mutation-directed therapies targeting genetic abnormalities such as FLT3 and NPM1 are reshaping treatment standards, enabling clinicians to select the most effective therapies for specific patient populations while reducing unnecessary toxicity. As a result, targeted therapies have emerged as the leading drug class, expected to account for 36% of market share in 2026. The growing availability of mutation-specific drugs and novel targeted agents is expanding treatment options for patients with genetically defined AML subtypes, offering enhanced efficacy and improved tolerability compared to conventional approaches.
Among disease types, newly diagnosed AML represents the largest patient segment, projected to hold 48% of market share in 2026. Initial treatment regimens generate the highest therapy volumes as patients typically begin treatment immediately following diagnosis and risk assessment. Hospitals remain the dominant end-user, accounting for 55% of market demand, due to the intensive inpatient management required for AML treatment, including blood transfusion support, chemotherapy administration, and continuous monitoring. Similarly, hospital pharmacies maintain a 49% market share, reflecting the complexity of AML therapies that require specialized handling and monitoring.
One of the strongest growth drivers is the increasing availability of therapies for relapsed and refractory AML. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are expanding options for patients who previously had limited alternatives. Recent regulatory approvals and clinical advancements continue to strengthen the treatment landscape, offering new hope for difficult-to-treat cases. According to Shambhu Nath Jha, Principal Consultant at Fact.MR, "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability."
Regional markets also display strong growth potential. South Asia and East Asia are emerging as high-growth regions due to expanding cancer care infrastructure and increasing access to molecular diagnostics. India is projected to grow at 11.8% CAGR, China at 10.9%, the United States at 8.7%, Germany at 7.9%, and Japan at 7.4%. North America continues to lead market revenues due to strong specialty pharmacy networks and high healthcare spending, while Western Europe remains an important market supported by advanced hematology care centers and established reimbursement frameworks.
The competitive landscape features leading pharmaceutical companies such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc. These industry participants are investing heavily in precision medicine, molecular diagnostics partnerships, clinical trials, and patient access programs to strengthen their positioning. The future outlook remains positive as innovation continues to reshape the global hematology treatment landscape, with continued advances in precision oncology, molecular diagnostics, and lower-intensity treatment regimens expected to further expand treatment opportunities and improve patient outcomes. For more details, the full report is available at https://www.factmr.com/report/acute-myeloid-leukemia-therapeutics-market.
